Adricin (a type of chemotherapy agent) is a specialized treatment used for various cancers. Its use is relevant for treating the underlying illness, and it is generally applied across conditions presenting with systemic or localized malignant discomfort. This includes relevance across a number of conditions, such as acute leukemias, lymphomas, and various solid tumors like breast, ovarian, and lung cancer.

This medication's primary purpose is used in areas where short-term symptom management is appropriate and is relevant for managing the underlying illness.

Core Therapeutic Goals

Adricin is commonly used to help with symptom clusters that result directly from the disease, addressing both symptoms related to physical discomfort (relevant in conditions characterized by periods of heightened symptoms) and symptoms related to systemic imbalance (such as fatigue or weight loss associated with widespread malignant activity). The treatment is relevant when supportive symptom management is appropriate, applied in clinical settings that involve acute or unstable symptom patterns. Its use contributes to improved day-to-day comfort by contributing to easing the overall symptom load.

Quick Fact: Relief for Systemic Discomfort

Adricin helps address the systemic discomfort associated with advanced cancer, assisting with maintaining functional stability when symptoms are more noticeable.

Regulatory References

1. National Cancer Institute overview of Doxorubicin Hydrochloride

Eligibility Map: Who can and cannot use Adricin

The eligibility for Adricin (Doxorubicin hydrochloride) is strictly governed by regulatory documentation and is highly dependent on a patient's pre-existing health and prior treatment exposure. Its use is established for both adults and pediatric patients across approved cancer indications.

Absolute Contraindications

Adricin is strictly prohibited for several populations as defined by regulatory labeling:

• Patients who have reached the maximum lifetime cumulative dose of doxorubicin or other anthracyclines.
• Individuals with severe myocardial insufficiency or who have recently experienced a myocardial infarction.
• Patients presenting with severe hepatic impairment or severe persistent drug-induced myelosuppression prior to treatment.
• Any history of severe hypersensitivity to doxorubicin or related compounds.

Age and Reproductive Status

Use is restricted in patients with less severe forms of hepatic or renal impairment, requiring formal dose modification as stipulated in the official labeling.

Interactions with other medicines and products

Official regulatory documents define the Doxorubicin interaction profile primarily by identifying substances that alter drug exposure and those that pose risks due to additive toxic effects.

Documented Interaction Classifications

Administration Requirements

Specific timing constraints are required for certain co-administered agents. Doxorubicin must be administered prior to Paclitaxel if they are given together. Additionally, anthracycline therapy must be avoided for up to 7 months following the cessation of Trastuzumab. For pediatric patients, the risk of developing delayed cardiotoxicity is heightened by concomitant cardiotoxic therapies, requiring specialized consideration in this population.

The active molecule in Adricin, Doxorubicin, exerts its pharmacodynamic action through three simultaneous molecular mechanisms targeting cellular proliferation. The primary action involves intercalation, where the molecule physically inserts itself into the DNA helix, imposing torsional stress that blocks replication and transcription. This dual action is compounded by Topoisomerase II ( TOP2) poisoning; Doxorubicin stabilizes the DNA- TOP2 cleavage complex, preventing re-ligation and resulting in uncompensated DNA double-strand breaks ( DSBs). The accumulation of DSBs triggers the DNA Damage Response ( DDR) pathway, enforcing G2/M cell cycle arrest and subsequent apoptosis (programmed cell death). Concurrently, Doxorubicin participates in redox cycling within the cell, leading to the massive generation of Reactive Oxygen Species ( ROS). These free radicals inflict non-specific oxidative damage on lipids, proteins, and membranes, contributing to the overall physiological process of cell disruption and the elimination of cells characterized by a high mitotic index.

Instruction Map: How to use Adricin — Official Administration Guidelines

Administration of Adricin (Doxorubicin Hydrochloride) is governed by specific clinical protocols to ensure standardized, controlled delivery.

Connection to the Overall Use Protocol

These instructions establish a highly controlled protocol where dosing is strictly determined by Body Surface Area and adjusted for specific organ function. The cyclic frequency patterns and strict cumulative dose constraint ensure standardized administration and long-term exposure management, with detailed preparation and delivery rules governing the precise intravenous process.

Research Evidence / Overview of Studies for Adricin (Doxorubicin)

The research evidence for Adricin is drawn from official sources and large-scale, peer-reviewed clinical trials, primarily focusing on its use as a component within combination chemotherapy regimens for multiple types of cancer. This overview explains the nature of the available research, the metrics studied, and areas where evidence remains limited or uncertain.

Evidence for Use in Solid Tumors: Breast and Ovarian Cancer

Research for Adricin has been conducted through studies in solid tumors, primarily using Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies typically measure high-level metrics such as Overall Survival (OS) and the duration of Disease-Free Survival (DFS), particularly in the adjuvant setting (after initial surgery) for breast cancer. Studies documented the patterns of survival and recurrence rates observed over the study period. Because Adricin is consistently used in multi-drug combination protocols, it is difficult to isolate the contribution of the single agent. Findings varied across studies when comparing different drug formulations, and the evidence base for certain treatment sequences is still developing.

Evidence for Use in Hematologic Malignancies: Leukemias and Lymphomas

Adricin was examined in numerous RCTs in the context of treating blood cancers, including leukemias and lymphomas. Research examined key clinical outcomes such as measurements of remission status, Event-Free Survival, and Overall Survival in both adult and pediatric patient groups. Findings describe patterns related to outcomes observed within specific established drug regimens (e.g., CHOP or ABVD combinations). A key limitation is that the single-agent contribution remains uncertain, as the research always tests the full combination protocol.

Long-Term Observation and Research Uncertainty

Research often requires extended observation periods; for instance, some adjuvant breast cancer studies have tracked patients for ten years or more. However, available follow-up durations were limited in many contexts, and data for outcomes far beyond five years often stem from observational reports. Adricin was evaluated in both adult and pediatric patients, but limited information is available regarding long-term outcomes in very specific subgroups. The evidence base for rare disease sub-types remains insufficient, and comparative research against newer classes of non-chemotherapy treatments is constantly evolving.

Key Studies & References

1. Doxorubicin (Adriamycin, Rubex): Drug Monograph (MedlinePlus)

Common questions about Adricin (FAQ)

Q: What is the main reason a doctor would prescribe Adricin?

Adricin (Doxorubicin) is officially approved for the treatment of specific types of cancer in both adult and pediatric populations. The official indications include certain types of breast cancer, bladder cancer, lymphomas, and leukemias. It is classified as an antineoplastic and cytotoxic agent.

Q: Are there any documented cases of Adricin causing fatigue or sleepiness?

Official safety information lists general fatigue as a very common side effect. Although rare, other central nervous system effects such as dizziness and somnolence (sleepiness) have also been reported with the administration of Doxorubicin.

Q: What is the purpose of the different strengths Adricin is available in?

Adricin is available in different vial sizes (e.g., 20 mg/vial and 50 mg/vial) to allow for accurate and flexible dose calculation. Because the dose is strictly determined by the patient’s Body Surface Area (mg/m^2), these different strengths help facilitate the calculation and preparation of the personalized dosage.

Q: Is Adricin known to cause weight gain or weight loss?

Official regulatory labels do not explicitly list weight gain or weight loss as common or very common side effects. However, gastrointestinal adverse reactions such as nausea, vomiting, diarrhea, and loss of appetite (anorexia) are listed as very common.

Q: Is it normal to feel a mild headache when first starting Adricin?

Headache is a reported possible adverse reaction and can occur as part of acute infusion-related reactions. Fever due to low blood counts (myelosuppression) is also a common occurrence.

Q: Can Adricin be taken with over-the-counter pain relievers like ibuprofen?

Regulatory documents warn that the drug interacts with substances that affect certain liver enzymes and transport proteins (CYP3A4/2D6, P-gp). While specific over-the-counter pain relievers are not named, caution is advised with all new medications due to the potential for interactions that could affect the balance of blood cell counts.

Q: Do any official documents describe Adricin as being 'addictive'?

No. The active ingredient, Doxorubicin, is classified only as a human prescription drug. It is not listed under any DEA schedule for controlled substances and is not described in official documents as having any abuse potential.

Q: Are there any specific lifestyle changes that official sources suggest when using Adricin?

Official patient guidance describes the use of sunscreen and protective clothing when outdoors to mitigate the risk of photosensitivity and a severe skin reaction called radiation recall. Information also describes the need for caution to prevent cuts or injuries due to the risk of bleeding caused by low platelet counts.

Q: Is Adricin used to treat the underlying condition or just the symptoms?

Adricin is classified as a cytotoxic and antineoplastic agent. This means its mechanism is to directly interfere with and kill dividing cells, such as cancer cells. Its primary function is to address the underlying cause of unwanted cellular proliferation, not just to manage symptoms.

Q: Can I take vitamins while using Adricin?

Official information indicates that the drug’s activity may be affected by certain supplements and antioxidants. For example, herbal supplements that induce liver enzymes, like St. John's wort, are noted in official documents to be avoided as they may decrease the drug's effectiveness. Any vitamins or supplements should be reviewed with a healthcare provider to assess potential interaction risks.

Q: Does Adricin affect the ability to drive or operate machinery?

Regulatory documents indicate that Doxorubicin generally has no or negligible influence on a person’s ability to drive. However, patients who experience side effects such as dizziness, somnolence (sleepiness), or fatigue should be aware of the official guidance to avoid driving or operating heavy machinery.

Q: Is Adricin a generic drug or is it only available as a brand name?

The active ingredient, Doxorubicin Hydrochloride, is the approved generic name for the drug. It is available in both generic formulations and under various brand names like Adriamycin, depending on the manufacturer and location.

Q: Why is there a warning about grapefruit juice and Adricin?

Grapefruit juice is a strong inhibitor of specific liver enzymes and transport proteins involved in drug metabolism (CYP3A4 and P-glycoprotein). Avoiding it is advised because it may increase the concentration of Doxorubicin in the blood, which raises the risk of serious side effects like cardiotoxicity and severe myelosuppression.

Q: How is Adricin eliminated from the body?

After being given intravenously, the drug is removed from the body through a process called multiphasic disposition. It undergoes metabolism to its major metabolite, doxorubicinol. The time it takes for the drug concentration to decrease by half (terminal half-life) typically can range from 20 to 48 hours.

Q: What does the patient information leaflet say about alcohol consumption with Adricin?

Official regulatory documents do not list alcohol as a specific drug interaction. However, standard patient guidance often indicates the importance of reviewing alcohol use with a healthcare provider, especially since impaired liver function could potentially increase the drug’s concentration and effects in the body.

Q: What is Adricin's effect on blood pressure?

Official labeling lists hypotension (low blood pressure) as a symptom that has been reported during acute infusion-related reactions. The drug's most critical cardiac effect is related to long-term damage to the heart muscle, known as cardiomyopathy.

Q: Can Adricin be taken by elderly patients?

Regulatory documents confirm that Adricin can be administered to elderly patients. However, documents state that dosage adjustment is required (e.g., lower doses or longer cycle intervals) to manage potential risks in this population.

Q: Are there any rare side effects of Adricin that patients should be aware of?

In addition to the common and serious risks, official safety documents report rare effects that patients should be aware of. These include issues like inflammation of the eye (keratitis), hyperpigmentation of the nailbeds, and a severe skin reaction known as radiation recall reaction.

Q: Is it necessary to have routine blood work done while on Adricin?

Official labeling describes the need for continuous monitoring due to the risk of cardiotoxicity and severe myelosuppression (low blood counts). The labeling stipulates the assessment of Left Ventricular Ejection Fraction (LVEF) before and regularly during treatment.

Q: What is the general duration of treatment with Adricin?

Single-agent treatment is administered in cycles, typically repeated every 21 days (3 weeks). The total duration of treatment is strictly limited by the maximum cumulative dose, which is a mandatory safety constraint designed to manage the long-term risk of cardiotoxicity.

Official Storage and Disposal Requirements for Adricin

Adricin (Doxorubicin HCl) storage and disposal are strictly governed by regulatory documentation to ensure safety and stability. This medication must be stored under refrigerated conditions, specifically between 2 C and 8 C (36 F and 46 F). The product must be actively protected from light and kept in its original outer carton.

It is officially required that this medicine be stored out of the reach of children.